טוען...
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy involves some significant safety challenges, such as cytokine release...
שמור ב:
| הוצא לאור ב: | J Hematol Oncol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5210295/ https://ncbi.nlm.nih.gov/pubmed/28049484 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0379-6 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|